FDA Warns Websites Marketing Unapproved Opioids

Share this content:
FDA Warns Websites Marketing Unapproved Opioids
FDA Warns Websites Marketing Unapproved Opioids

MONDAY, June 11, 2018 (HealthDay News) -- Nine online networks, operating 53 websites, have been warned that they must stop illegally marketing potentially dangerous, unapproved, and misbranded versions of opioid medications, according to the U.S. Food and Drug Administration.

As part of the effort to crack down on sales of illegal narcotics over the internet, a summit will be hosted with stakeholders to find new ways to collaborate and address these issues. In addition, the FDA will be taking action against companies whose websites break the law. Warning letters were sent to nine online networks; these will be followed by additional steps to prevent the flow of illegal, unapproved opioids.

Patients who buy prescription medicines from illegal online pharmacies may be putting their health at risk as these products could be counterfeit, contaminated, expired, or unsafe. In violation of the Federal Food, Drug, and Cosmetic Act, the websites offer opioids for sale that are misbranded and new drugs that are unapproved. The companies have been asked to respond within 10 working days, and are directed to inform the agency of specific actions taken.

"This illegal online marketing of unapproved opioids is contributing to the nation's opioid crisis," FDA Commissioner Scott Gottlieb, M.D., said in a statement. "The new warning letters are part of a comprehensive campaign to target illegal sales of unapproved opioids."

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »